Sign Out
Advise the patient to read the Instructions for Use.
Administration Instructions: Provide proper training to patients and/or caregivers on proper subcutaneous injection technique, including aseptic technique, and the preparation and administration of DUPIXENT prior to use. Advise patients to follow sharps disposal recommendations [see Dosage & Administration and Instructions for Use as follows].
Hypersensitivity: Advise patients to discontinue DUPIXENT and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions [see Hypersensitivity under Precautions].
Conjunctivitis and Keratitis: Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop [see Conjunctivitis and Keratitis under Precautions].
Eosinophilic Conditions: Advise patients to notify their healthcare provider if they present with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis [see Eosinophilic Conditions under Precautions].
Not for Acute Asthma Symptoms or Deteriorating Disease: Inform patients that DUPIXENT does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with DUPIXENT [see Acute Asthma Symptoms or Deteriorating Disease under Precautions].
Reduction in Corticosteroid Dosage: Inform patients to not discontinue systemic corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy [see Reduction of Corticosteroid Dosage under Precautions].
Patients with Co-morbid Asthma: Advise patients with atopic dermatitis who have co-morbid asthma not to adjust or stop their asthma treatment without talking to their physicians [see Patients with Co-morbid Asthma under Precautions].
